LATAM rapid-startup archetypes: Chile, Costa Rica, Panama, and El Salvador selection matrix

Four countries. Two archetypes. One decision: which startup design matches the evidence your board, QA, and first-patient-in date actually need.

I am Julio Martinez-Clark, CEO of bioaccess®. This is Part 3 of the Latin America rapid-startup archetypes series — the comparative framework for Chile, Costa Rica, Panama, and El Salvador. Part 1: pure ethics committee approval. Part 2: parallel review models. Corridor overview: fast-track FIH corridor. Indicative clocks only — confirm on filing day. Not legal advice.

The two archetypes side by side

Country cards for Clinical Ops, CMOs, and RA Directors

Chile

• Archetype: Pure ethics.
• Clock to watch: Accredited CEC under Decreto 114 — 45 calendar days from complete submission.
• Ministerial involvement: Not an ANAMED-style pharma IND sequential review for devices. ISP issues investigational-device import / provisional research-use authorization based on CEC clearance.
• Operational lead time to FPI: Ethics calendar + ISP import readiness + site director authorization. Plan weeks after a clean CEC letter, not months of ministry protocol science.
• Select Chile when: You want a statutory ethics clock, strong data-rigor perception, and a device path that does not wait on centralized pharma IND machinery.

Costa Rica

• Archetype: Pure ethics.
• Clock to watch: Written approval from a CONIS-accredited CEC, then CONIS registration before execution.
• Ministerial involvement: CONIS sits under the Ministry of Health structure for accreditation and registry. MINSA does not run a sequential protocol scientific review after ethics as the critical path.
• Operational lead time to FPI: CEC decision + CONIS registration + site institutional authorization. Combined ethics-plus-registry work commonly lands in a weeks-to-low-months band when the Spanish file is complete — ask for a study-specific calendar.
• Select Costa Rica when: You want Central American infrastructure, English-friendly operations, and an ethics-led start without inventing a ministry co-review that the archetype does not sell.

Panama

• Archetype: Parallel review.
• Clock to watch: Decreto Ejecutivo 21/2026 Art. 91 — MINSA and CNBI-accredited Type II CBI evaluate simultaneously via RESEGIS mechanics. Complete-file startup often ~30–45 days.
• Ministerial involvement: Explicit and concurrent. Registration on RESEGIS is mandatory before execution.
• Operational lead time to FPI: Parallel clearance + import / DNFD touches where required + site activation. The sprinter reputation is real when the dossier is Spanish-complete on day one.
• Select Panama when: You need ministry evaluation on the protocol and still need a weeks-scale startup. Use Type II, not Type I.

El Salvador

• Archetype: Parallel review.
• Clock to watch: Unified SRS-CNEIS-ES submission; CNEIS pleno ~4–6 weeks; overall clearance typically 30–60 days.
• Ministerial / authority involvement: SRS and CNEIS review concurrently from one digital file.
• Operational lead time to FPI: Platform clearance + hospital contracting + import readiness. Cost position is often favorable versus Panama; population depth still constrains recruitment modeling.
• Select El Salvador when: You want one ethics body, one regulator, one submission — authority validation without sequential delay.

Selection matrix — five filters before you pick

1. Do you need a national regulator’s protocol evaluation on the docket?
   Yes → Panama or El Salvador. No → Chile or Costa Rica.
2. Is your pain sequential backlog or ethics capacity?
   Sequential backlog → parallel archetype. Ethics calendar / Spanish file quality → fix the dossier before you change countries.
3. Device vs drug path?
   Chile’s device story (outside ANAMED pharma IND; ISP import after CEC) is a specific MedTech advantage. Confirm drug paths separately — do not copy-paste the device matrix onto every IND.
4. Recruitment honesty
   All four corridor countries are smaller than Brazil, Mexico, or Colombia. Fast startup is worthless if screening math is fiction. Model prevalence before you celebrate a 45-day ethics clock.
5. Import and site reality
   FPI is ethics/regulator clearance plus device or drug on site plus contracts signed. Parallel review does not ship inventory. Pure ethics does not either.

Indicative lead times to first-patient-in

Use these as planning bands for early-phase programs with a complete Spanish dossier, not as guarantees:

• Chile: CEC 45-calendar-day frame + ISP import + site authorization → often a weeks-scale path after complete ethics submission.
• Costa Rica: CONIS-accredited CEC + CONIS registration + site authorization → weeks to low months depending on committee cadence and file quality.
• Panama: Parallel Type II + MINSA via RESEGIS → ~30–45 days to clearance on a complete file; FPI follows import and site readiness.
• El Salvador: SRS-CNEIS-ES concurrent review → typically 30–60 days to clearance; CNEIS pleno often 4–6 weeks inside that band.

If someone sells you “15 days to FPI” without naming dossier completeness, import status, and site contracts, they are selling a press line, not an operating plan. bioaccess® has activated fast Panama files; we still separate clearance clocks from first-patient clocks.

How this series maps to the corridor post

The corridor article answers “why these four countries feel fast.” This series answers “which legal design are you buying.” Speed without archetype clarity produces the wrong country for the wrong diligence question. Put both documents in the same diligence binder.

Worked examples (no client names)

Example A — implantable early feasibility, US IDE still months out. Board wants first-in-human data and does not require a ministry co-signature on the protocol science. Chile’s CEC clock under Decreto 114 plus ISP import after CEC is the cleaner fit than forcing a parallel-review country for optics.

Example B — injectable or higher-visibility program where RA wants regulator eyes on the protocol. Panama Art. 91 parallel evaluation or El Salvador SRS-CNEIS-ES concurrent review answers the diligence question without a 6–12 month sequential stack.

Example C — multi-country early program. Use Costa Rica or Chile for an ethics-led first site while a Panama or El Salvador file runs in parallel for authority-validated evidence. That is portfolio design. It is not “pick the fastest logo.”

Diligence questions to send your CRO

1. Which archetype are you selling me, in one sentence, with the named statute or platform?
2. What starts the clock — complete-file date or first email?
3. What is explicitly not included in the clearance clock (import, contracts, pharmacy)?
4. For Panama: Type II CBI name and RESEGIS registration owner?
5. For El Salvador: who holds the SRS-CNEIS-ES account and who answers queries inside the platform?
6. For Chile: which accredited CEC and what is the ISP import dependency after the CEC letter?
7. For Costa Rica: which CONIS-accredited CEC and when does CONIS registration occur relative to site activation?

If the answers smear archetypes together, restart the country conversation before you restart the translation budget.

Operator recommendation

• MedTech FIH founder avoiding US IDE queue, wants ethics-led start: start with Chile or Costa Rica (Part 1).
• Sponsor whose QA/RA needs concurrent authority evaluation: start with Panama or El Salvador (Part 2).
• Portfolio with mixed programs: do not force one archetype. Match each protocol to the filter list above.

bioaccess® — the First-in-Human CRO for medical devices in Latin America since 2010 — builds the dossier to the archetype you chose, not the one that sounds faster in a slide. Global Trial Accelerators™ and the country hubs on bioaccessla.com exist so your team can verify clocks against named instruments: Ley 20.120, Decreto 114, Ley 9234 / CONIS, Decreto Ejecutivo 21/2026 Art. 91, SRS-CNEIS-ES.

Talk with bioaccess® when you need the four-country matrix turned into a study-specific startup calendar with Spanish file ownership, import sequencing, and an honest FPI date.